ABL Bio Successfully Concludes ABL503 Poster Presentation at ESMO IO
ABL Bio, a company specializing in bispecific antibodies, announced on December 12 that it successfully concluded a poster presentation for ABL503 (Ragistomig) at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO IO) 2025, held on December 10 (local time).
ABL503 is a PD-L1 and 4-1BB bispecific antibody jointly developed by ABL Bio and NovaBridge Biosciences (formerly iMAP). It is designed so that immune cell activation via 4-1BB occurs only within the tumor microenvironment where PD-L1 is expressed. Blocking PD-1/PD-L1 serves to inhibit cancer cells, while 4-1BB is a target involved in enhancing the proliferation and immune memory capacity of T cells, which are immune cells.
The monotherapy with ABL503 administered every six weeks (Q6W) was evaluated in 20 patients with relapsed or refractory solid tumors who had previously received immuno-oncology (IO) therapy and whose tumors expressed PD-L1. Among them, 17 patients were included as efficacy evaluable subjects. These clinical trial participants were confirmed to be a patient group with significant unmet medical needs, as they had no further standard treatment options available.
According to the poster presented, despite extending the dosing interval of ABL503 from every two weeks (Q2W) to every six weeks, a disease control rate (DCR) of 58.8% was reported, indicating that encouraging antitumor activity was maintained. Partial responses (PR) were reported in two patients who had previously been exposed to PD-(L)1 inhibitors but had relapsed or were refractory to treatment.
In addition, with ABL503 monotherapy administered every six weeks, treatment-related grade 3 or higher adverse events occurred in 15% (3/20) of patients, and grade 3 or higher elevations in liver function tests were observed in 5% (1/20), showing that the overall safety profile was significantly improved. None of the patients who received ABL503 every six weeks discontinued the clinical trial due to adverse events occurring during treatment, and notably, there were no reported cases of cytokine release syndrome (CRS).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Sanghoon, CEO of ABL Bio, stated, "What is particularly noteworthy about this data is that, despite the reduced drug exposure due to the extended dosing interval, the immune memory capacity of T cells was enhanced, and the tumor microenvironment that previously hindered T cell activation was also favorably improved. Based on these results, ABL503 at a dose of 3 mg/kg administered every six weeks is being evaluated as a candidate dose for future combination therapy development. Moving forward, ABL Bio plans to expand the clinical strategy for ABL503 to combination therapies and seek out the optimal partners."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.